Welcome to our dedicated page for Caredx SEC filings (Ticker: CDNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CareDx, Inc. regulatory filings document the public-company record for a Nasdaq-listed precision medicine company serving transplant patients and caregivers. The company’s 8-K and proxy materials cover operating and financial results for testing services, patient and digital solutions, laboratory products, and clinical or regulatory disclosures tied to non-invasive molecular testing for organ transplantation.
CareDx filings also address material agreements, capital-structure matters for its common stock, shareholder voting items, board governance, executive compensation, inducement and other equity awards, and officer-role changes. Other-event disclosures include governance and legal-contingency materials, including shareholder derivative litigation settlement documents when filed.
CareDx, Inc. President and CEO John Walter Hanna Jr. reported an open-market sale of 17,683 shares of Common Stock on June 15, 2026 at a weighted average price of $24.0274 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 13, 2024.
After this transaction, he continues to directly hold 631,959 shares of CareDx common stock, according to the filing.
CareDx, Inc. director Hannah Valantine reported both an equity grant and a share sale. On June 12, 2026, she acquired 9,795 shares of Common Stock as a grant with no cash paid, represented by restricted stock units that vest 100% on the earlier of the one-year anniversary of grant or immediately before the first Annual Meeting after the grant date, subject to continuous service. On June 15, 2026, she sold 12,103 shares of Common Stock in an open-market transaction at a weighted average price of $23.1123 per share, with individual sale prices ranging from $23.00 to $23.30. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025, and she held 36,686 shares directly after the sale.
COURNOYER CHRISTINE reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director Christine Cournoyer received a grant of 9,795 shares of common stock in the form of restricted stock units. The RSUs vest 100% on the earlier of one year after the grant date or immediately before the first annual meeting after the grant, subject to continued service. Following this grant, she directly holds 58,943 shares.
CareDx, Inc. reported that director Richard Bryan Riggsbee acquired 9,795 shares of common stock through a grant of restricted stock units. These RSUs were awarded at no cash cost per share and are a form of equity compensation, not an open-market purchase.
According to the filing, all of the RSUs vest 100% on the earlier of the one-year anniversary of the grant date or the day immediately before the first Annual Meeting that occurs after the grant date, subject to his continuous service. Following this award, Riggsbee directly holds 39,312 shares of CareDx common stock.
Cohen Fred E reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director Fred E. Cohen received an equity grant of 9,795 shares of Common Stock in the form of restricted stock units. These RSUs vest 100% on the earlier of one year from the grant date or the day before the first Annual Meeting after the grant date, subject to his continuous service. Following this award, he holds 165,060 shares directly.
Gunasekaran Suresh reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director Suresh Gunasekaran reported receiving an equity award of 9,795 shares of Common Stock, represented by restricted stock units (RSUs). These RSUs vest 100% on the earlier of one year after the grant or the day immediately before the first Annual Meeting after the grant, subject to his continuous service. Following this award, he holds 37,248 shares directly.
Bickerstaff George reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director George Bickerstaff received an equity award in the form of 9,795 shares of Common Stock represented by restricted stock units. These RSUs were granted at no cash cost to him and are part of his compensation.
The RSUs vest 100% on the earlier of the one-year anniversary of the grant date or the day immediately before the first Annual Meeting that occurs after the grant date, subject to his continuous service through that time. Following this award, he holds 154,061 shares of Common Stock directly.
Goldberg Michael reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director Michael Goldberg reported receiving a grant of 9,795 restricted stock units (RSUs) of common stock at no cash cost, as a compensation award rather than an open‑market purchase.
The RSUs vest 100% on the earlier of the one‑year anniversary of the grant or the day immediately before the first Annual Meeting after the grant, subject to his continuous service. Following this award, he directly holds 195,737 shares of common stock.
CareDx, Inc. President and CEO John Walter Hanna Jr. reported an open-market sale of 21,998 shares of Common Stock on June 11, 2026 at a weighted average price of $24.0223 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 13, 2024, and left him with 649,642 shares held directly.